48/120
2.0 / 5 stars
All 120 Win/Lose results shown below
BMY Roast Me summary
BRISTOL MYERS SQUIBB CO (BMY). Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Win.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Win.
- 2025-Q4: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
Trailing 1 year (4 quarters): 4 wins, 8 lossesLast fetched: 25 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q21/3 |
LoseBMY / S&P -4.02% / 15.20% |
LoseBMY / S&P 3.11% / 15.00% |
WinBMY / S&P 83.06% / 50.40% |
| 2026-Q12/3 |
WinBMY / S&P 13.77% / -4.33% |
LoseBMY / S&P 1.78% / 11.30% |
WinBMY / S&P 33.33% / 27.70% |
| 2025-Q41/3 |
WinBMY / S&P 21.24% / 2.65% |
LoseBMY / S&P -0.22% / 9.00% |
LoseBMY / S&P BMY unavailable / 13.40% |
| 2025-Q30/3 |
LoseBMY / S&P -1.29% / 8.12% |
LoseBMY / S&P 1.26% / 4.61% |
LoseBMY / S&P BMY unavailable / 13.45% |
| 2025-Q20/3 |
LoseBMY / S&P -23.28% / 10.94% |
LoseBMY / S&P 2.57% / 4.83% |
LoseBMY / S&P BMY unavailable / 10.63% |
| 2025-Q11/3 |
WinBMY / S&P 9.02% / -4.27% |
LoseBMY / S&P 4.62% / 4.98% |
LoseBMY / S&P BMY unavailable / 10.57% |
| 2024-Q42/3 |
WinBMY / S&P 10.54% / 2.41% |
WinBMY / S&P 7.32% / 5.25% |
LoseBMY / S&P -214.25% / 6.15% |
| 2024-Q31/3 |
WinBMY / S&P 26.48% / 5.89% |
LoseBMY / S&P 5.56% / 5.89% |
LoseBMY / S&P -191.12% / 6.11% |
| 2024-Q20/3 |
LoseBMY / S&P -22.53% / 4.28% |
LoseBMY / S&P 2.93% / 5.38% |
LoseBMY / S&P -186.70% / 5.12% |
| 2024-Q10/3 |
LoseBMY / S&P 6.92% / 10.56% |
LoseBMY / S&P -0.68% / 5.71% |
LoseBMY / S&P -190.38% / 5.59% |
| 2023-Q41/3 |
LoseBMY / S&P -10.70% / 11.69% |
LoseBMY / S&P -2.50% / 6.81% |
WinBMY / S&P 30.85% / 7.78% |
| 2023-Q31/3 |
LoseBMY / S&P -8.44% / -3.27% |
LoseBMY / S&P -3.86% / 7.52% |
WinBMY / S&P 28.34% / -5.03% |
| 2023-Q21/3 |
LoseBMY / S&P -6.97% / 8.74% |
LoseBMY / S&P -4.15% / 9.50% |
WinBMY / S&P 24.92% / -8.57% |
| 2023-Q11/3 |
LoseBMY / S&P -2.91% / 7.50% |
LoseBMY / S&P -2.37% / 10.77% |
WinBMY / S&P 21.63% / -15.69% |
| 2022-Q41/3 |
LoseBMY / S&P 1.98% / 7.56% |
LoseBMY / S&P -0.49% / 11.88% |
WinBMY / S&P -5.45% / -17.99% |
| 2022-Q30/3 |
LoseBMY / S&P -7.68% / -4.88% |
LoseBMY / S&P 2.79% / 13.47% |
LoseBMY / S&P BMY unavailable / -1.41% |
| 2022-Q21/3 |
WinBMY / S&P 6.17% / -16.10% |
LoseBMY / S&P 6.22% / 13.71% |
LoseBMY / S&P BMY unavailable / 11.04% |
| 2022-Q11/3 |
WinBMY / S&P 19.03% / -4.60% |
LoseBMY / S&P 9.69% / 15.97% |
LoseBMY / S&P BMY unavailable / 42.23% |
| 2021-Q40/3 |
LoseBMY / S&P 5.37% / 11.03% |
LoseBMY / S&P 9.09% / 15.00% |
LoseBMY / S&P BMY unavailable / 96.40% |
| 2021-Q31/3 |
LoseBMY / S&P -10.07% / 0.58% |
WinBMY / S&P 15.42% / 10.77% |
LoseBMY / S&P BMY unavailable / 69.42% |
| 2021-Q21/3 |
LoseBMY / S&P 5.85% / 8.55% |
WinBMY / S&P 27.31% / 6.58% |
LoseBMY / S&P BMY unavailable / 51.81% |
| 2021-Q11/3 |
LoseBMY / S&P 2.57% / 6.17% |
WinBMY / S&P 38.07% / -1.06% |
LoseBMY / S&P -545.16% / 7.39% |
| 2020-Q41/3 |
LoseBMY / S&P 4.49% / 12.15% |
WinBMY / S&P 62.62% / -3.72% |
LoseBMY / S&P -298.51% / -33.42% |
| 2020-Q31/3 |
LoseBMY / S&P 3.32% / 8.93% |
WinBMY / S&P 62.97% / -2.04% |
LoseBMY / S&P -108.70% / -27.10% |
| 2020-Q21/3 |
LoseBMY / S&P 6.36% / 20.54% |
WinBMY / S&P 46.13% / -0.46% |
LoseBMY / S&P -107.67% / -27.11% |
| 2020-Q12/3 |
WinBMY / S&P -12.55% / -19.60% |
WinBMY / S&P 33.14% / 3.47% |
LoseBMY / S&P -80.25% / -14.75% |
| 2019-Q42/3 |
WinBMY / S&P 27.65% / 9.07% |
WinBMY / S&P 15.89% / 5.36% |
LoseBMY / S&P -33.22% / 2.99% |
| 2019-Q33/3 |
WinBMY / S&P 12.81% / 1.70% |
WinBMY / S&P 9.69% / 5.02% |
WinBMY / S&P 287.64% / 0.21% |
| 2019-Q22/3 |
LoseBMY / S&P -4.11% / 4.30% |
WinBMY / S&P 10.45% / 6.64% |
WinBMY / S&P 1475.00% / 8.65% |
| 2019-Q12/3 |
LoseBMY / S&P -7.49% / 13.65% |
WinBMY / S&P 10.68% / 8.12% |
WinBMY / S&P 450.88% / 14.29% |
| 2018-Q41/3 |
LoseBMY / S&P -15.73% / -13.52% |
LoseBMY / S&P 8.59% / 9.05% |
WinBMY / S&P 393.44% / 18.23% |
| 2018-Q31/3 |
WinBMY / S&P 12.99% / 7.71% |
LoseBMY / S&P 7.13% / 10.21% |
LoseBMY / S&P -64.96% / 19.06% |
| 2018-Q20/3 |
LoseBMY / S&P -11.95% / 3.43% |
LoseBMY / S&P 6.73% / 9.03% |
LoseBMY / S&P -91.27% / 14.46% |
| 2018-Q11/3 |
WinBMY / S&P 3.89% / -0.76% |
LoseBMY / S&P 5.38% / 7.68% |
LoseBMY / S&P -80.21% / 12.46% |
| 2017-Q40/3 |
LoseBMY / S&P -3.28% / 6.64% |
LoseBMY / S&P 6.94% / 7.03% |
LoseBMY / S&P -76.98% / 13.82% |
| 2017-Q33/3 |
WinBMY / S&P 15.19% / 4.48% |
WinBMY / S&P 11.36% / 5.68% |
WinBMY / S&P 27.00% / 17.57% |
| 2017-Q23/3 |
WinBMY / S&P 3.21% / 3.09% |
WinBMY / S&P 14.87% / 4.83% |
WinBMY / S&P 61.76% / 17.74% |
| 2017-Q12/3 |
LoseBMY / S&P -6.33% / 6.07% |
WinBMY / S&P 18.07% / 3.67% |
WinBMY / S&P 209.68% / 13.32% |
| 2016-Q43/3 |
WinBMY / S&P 9.13% / 3.82% |
WinBMY / S&P 17.31% / 2.09% |
WinBMY / S&P 184.95% / 7.05% |
| 2016-Q32/3 |
LoseBMY / S&P -26.69% / 3.85% |
WinBMY / S&P 11.74% / 0.20% |
WinBMY / S&P 88.68% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-28
| Metric | BMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 47.91% | 20.78% |
| Annualized return | 47.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-28
| Metric | BMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 24.18% | 83.14% |
| Annualized return | 4.43% | 12.86% |
10Y · 2016-09-01 to 2026-08-28
| Metric | BMY total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 66.87% | 319.30% |
| Annualized return | 5.25% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-25.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |